Johnson & Johnson (JNJ)

JNJ on New York Consolidated

101.55USD
30 Mar 2015
Change (% chg)

$1.21 (+1.21%)
Prev Close
$100.34
Open
$101.24
Day's High
$101.86
Day's Low
$100.76
Volume
6,060,862
Avg. Vol
9,186,365
52-wk High
$109.49
52-wk Low
$95.10

JNJ

Chart for JNJ

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $279,001.31
Shares Outstanding(Mil.): 2,780.56
Dividend: 0.70
Yield (%): 2.79

Financials

  JNJ Industry Sector
P/E (TTM): 17.60 40.31 40.78
EPS (TTM): 5.70 -- --
ROI: 15.32 16.86 16.19
ROE: 22.70 17.40 17.04
Search Stocks

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

6:27pm EDT

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

6:26pm EDT

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK, March 30 - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

6:07pm EDT

Pharmacyclics cancer drug successful as combination therapy: independent panel

- An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

UPDATE 1-Pharmacyclics cancer drug successful as combination therapy - independent panel

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

16 Mar 2015

CORRECTED-Independent panel recommends unblinding study after Imbruvica shows clear benefit

March 16 - An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs.

16 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Johnson & Johnson sues Glaxo over allergy ads as spring nears

NEW YORK, March 12 - Johnson & Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.

12 Mar 2015

Tylenol maker to pay $25 mln for selling metal-contaminated drugs

WASHINGTON - A Johnson & Johnson subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case, the U.S. Department of Justice said on Tuesday.

10 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks